ROGER WETLI APPOINTED AS CHIEF FINANCIAL OFFICER OF THE COMPANY

Zuerich, Switzerland, January 1st, 2024. Novago Therapeutics AG announces that Roger Wetli was appointed as Chief Financial Officer of the company effective January 01, 2024.

Roger Wetli will lead the finance and accounting organization and will report directly to Stefan Moese, CEO. Prior to joining NovaGo Therapeutics AG, Roger Wetli was Senior Director Tax and Finance at Neurimmune AG and Neurimmune Subone AG, Roger’s ongoing responsibilities span overseeing financial planning, financial reporting, controlling, treasury and tax strategies aligned with corporate objectives. Roger started his career and held several positions at big four consulting firms, with the focus on international tax planning and structuring. He further gained rich industry experience and expertise whilst working for a leading firm in the specialty chemical industry. He obtained his MBA (lic.oec.publ., Finance) from the university of Zurich, Switzerland and holds a diploma as certified Swiss tax expert. Stefan Moese, PhD CEO, commented: “As we intensify our outreach to additional investors for NovaGo, we are very pleased to welcome such an experienced college to our management team.”

STEFAN MOESE APPOINTED AS CHIEF EXECUTIVE OFFICER OF THE COMPANY

Zuerich, Switzerland, November 1st, 2023. Novago Therapeutics AG announces that Dr. Stefan Moese was appointed as Chief Executive Officer of the company effective November 01, 2023.

Dr. Moese will lead the company as its orientation shifts from pre-clinical towards clinical developments and strategic partnerships. Founder and former CEO, Prof. Martin E. Schwab, PhD, hon. MD will focus his efforts as Chief Scientific Officer and chairman of the BoD on the continued advancement of the preclinical package and on the expansion of mechanistic studies for various diseases. Prior to joining NovaGo Therapeutics AG, Dr. Stefan Moese was Vice President Research and Technology at Neurimmune AG. He has been responsible for management of the entire pre-clinical portfolio in collaboration with the Neurimmune’s CSO up to start of clinical development. He also has overseen the antibody technologies group and bioinformatics. Prior to Neurimmune, Stefan led various global teams in big pharma and biotech companies in Europe and US.  He holds a Ph.D. in infection biology (MPI Infection Biology and Humboldt University Berlin, Germany) .“NovaGo Therapeutics AG is well positioned to translate it’s extensive pre-clinical knowledge in the area of nerve repair to meaningful results for patients. I am very much looking forward to helping the company to transition into a clinical stage and bringing its strong value proposition into partnerships.” said Stefan Moese.

Prof. Martin E. Schwab, PhD, hon. MD, Chairman of the BoD of NovaGo Therapeutics AG Supervisory Board, commented: “As we look to the next phase of evolution for NovaGo, we are very pleased to have been able to recruit Stefan to develop the company to become a major player in the field of regenerative growth of nerve fibers.”